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ABSTRACT: The most potent inhibitor of Sphingosine Kinase
1 (SPHK1) so far identiﬁed is PF-543. The crystal structure
of SPHK1 in complex with inhibitor PF-543 to 1.8 Å resolution
reveals the inhibitor bound in a bent conformation analogous
to that expected of a bound sphingosine substrate but with
a rotated head group. The structural data presented will aid in
the design of SPHK1 and SPHK2 inhibitors with improved
properties.
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S phingosine kinases catalyze the conversion of sphingosineto sphingosine-1-phosphate (S1P), the ﬁnal step of S1P
biosynthesis.1−4 There are two sphingosine kinases: Sphingo-
sine Kinase 1 (SPHK1) is mostly localized to the cytosol while
Sphingosine Kinase 2 (SPHK2) is mostly nuclear.5−7 SPHK2
has 53% sequence identity with SPHK1, but SPHK2 has a large
insertion in the lipid binding domain of 134 residues, compared to
18 residues for the equivalent loop in SPHK1, and this insertion
contains a signiﬁcant proportion of proline residues indicating
structural disorder. SPHK1 and SPHK2 have some compensatory
activities, and while SPHK1 and SPHK2 double knockout mice
are embryonically lethal,8 individual knockouts remain viable,9 one
major reason being that absence of SPHK2 up-regulates SPHK1
expression. Potential individual roles in cell biology of SPHK1 and
SPHK2 have been recently reviewed.10,11 The links between S1P
formation and disease are strong, especially in relation to cancer
and inﬂammation.11−15
A variety of sphingosine kinase inhibitors have been
developed.16,17 However, most are analogues of sphingosine
and show only micromolar aﬃnity. Targeting the S1P pathway
has resulted in clinical use of one therapeutic agent, FTY720
(Fingolimod, Gilenya), approved for treatment of relapsing-
remitting multiple sclerosis.18 FTY720 inhibits the action of
SPHK1 and SPHK2 in phosphorylating sphingosine19 and is
itself phosphorylated by SPHK2 causing it to act as a functional
antagonist of sphingosine-1-phosphate receptor 1 (S1PR1 or
S1P1). This is achieved by inducing proteasomal degradation of
S1PR1 to create S1PR1 null T-lymphocytes that are unable to
egress from lymph nodes into the circulation.20 To avoid potential
issues with lipid analogues, including lack-of-speciﬁcity, some non-
sphingosine analogue inhibitors have also been developed,21−24
although the speciﬁcity for these is also not well characterized.
Recently, use of high-throughput screening and medicinal chem-
istry optimization allowed development of the non-lipid PF-543
(1, Chart 1).25 A Ki of 4.3 nM and more than 100-fold selectivity
for SPHK1 over SPHK2 were reported.25 Compound 1 showed
no eﬀect on endogenous ceramide levels but reduced S1P levels in
1483 head/neck carcinoma cells.25
Structures of SPHK1 were recently reported in complex with
inhibitor SKI-II and ADP and in complex with a bound lipid.26
These structures revealed the expected structural homology of
SPHKs to the diacylglycerol kinases, with the lipid bound in a
bent conformation in a completely enclosed largely hydro-
phobic pocket. These structures were used to develop an
optimized inhibitor with 20 nM aﬃnity, which was also
characterized structurally.27
Here, we have determined the crystal structure of SPHK1
with 1, the most potent SPHK1 inhibitor reported to date.
Analysis of the structure suggests ways to design inhibitors with
improved SPHK1 or SPHK2 selectivity, as well as ways to take
advantage of SPHK features that might allow improved
inhibitor selectivity over other enzymes in the ceramide/
sphingosine biosynthetic pathway.
Residues 81−449 of SPHK1 isoform 2 (NP_892010.2, NCBI
database) were cloned into a baculovirus expression system,
which was used to produce SPHK1 protein of high purity
suitable for crystallization. This is equivalent to 9−377 of isoform
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1 (NP_068807.2) or 1−363 of isoform 3 (NP_001136074.1),
with the crystallized construct containing N-terminal residues
with no equivalent in isoform 3. The protein was monomeric
in solution, showing a single peak on size-exclusion chroma-
tography, and was co-crystallized with 1 and ADP yielding
a structure of the SPHK1: 1 complex to 1.8 Å resolution
(Figure 1A), the best resolution yet reported for a SPHK1
crystal structure.
There were two molecules in the crystallographic asymmetric
unit. In each, SPHK1 residues 93−449 were resolved in the
electron density with the exception of the loop comprising
residues 312−317, which was disordered. This is the loop that
is greatly extended and predicted to be disordered in SPHK2,
so it is not surprising that it is also disordered in SPHK1. Mass
spectrometry showed the partial phosphorylation of the protein
but no phosphorylation site was obvious in the electron density
although the known site of ERK phosphorylation, Ser311
(Ser225 in SPHK1 isoform 3), is poorly ordered, being
adjacent to the disordered loop 312−317. Although residues
81−87 from the crystallized sequence are not conserved
between SPHK1 isoforms 1, 2, and 3, as this region was not
resolved in the electron density, there is no practical diﬀerence
in the sequence of the structure compared to those already
published,26 which used isoform 3 (NP_001136074.1).
The structure superimposes with the previous structure
of SPHK1:SKI-II:ADP26 with a root-mean-square deviation
(rmsd) of 0.52 Å over 333 Cα atoms. Although ADP was
added to the protein used for crystallization, as well as
compound 1, no ADP was visible in the electron density, and
the protein loops surrounding the nucleotide binding site
have among the highest temperature factors. In the structure
of SPHK1:SKI-II:ADP the ADP is also only visible in two out
of the six molecules in the asymmetric unit.26 The inhibitor 1
was, however, clearly resolved in the electron density in both
molecules in the asymmetric unit, bound in the completely
enclosed lipid binding site in the C-terminal domain of the
protein (Figure 1B).
Compound 1 adopts a bent conformation, mimicking the
conformation of the lipid observed bound in one of the previous
structures of SPHK1 (PDB ID 3VZB)26 with the terminal
phenyl ring occupying a hydrophobic pocket formed by residues
including Phe374 and Leucines 347, 354, and 405 (Figure 2).
Figure 1. Binding of PF-543 (1) to SPHK1. (A) Compound 1 shown
as a green spheres model binds in the lipid binding site in the C-
terminal domain of SPHK1, shown in red. The N-terminal nucleotide
binding domain of SPHK1 is shown in light green. (B) A 2F0 − Fc
map is shown contoured at 1.0σ around 1. The compound was well
resolved in the electron density. Only around the pyrrolidine head
group was the electron density slightly imperfect, which could perhaps
correspond to a small fraction of 1 in a conformation with the head
group rotated 180° or to a small proportion of SPHK1 with bound
lipid from the Sf 9 cells in place of 1 (see text for discussion).
Figure 2. Binding of PF-543 (1) to SPHK1 viewed from two opposite
directions with 1 shown in green. In each ﬁgure the residues in front of
1 have been removed for clarity. Residues are numbered for SPHK1
isoform 2 as crystallized; subtract 72 to get the equivalent residues in
isoform 1 or 86 to get the equivalent residues in isoform 3 (as used in
the previous structure of SPHK1).
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The terminal 1-substituted (R)-2-(hydroxymethyl)-pyrrolidine
is bound in the expected position for a lipid head group, adjacent
to the binding site for the ATP γ-phosphate. Hydrogen bonds
are formed from the pyrrolidine nitrogen and the hydroxyl of 1
to the side-chain of Asp264 (Figure 2). Asp264 is equivalent
to mouse SPHK1 Asp177, which was shown to be involved in
sphingosine recognition.28 Modeling suggested that this residue
binds the protonated amine of the SPHK1 inhibitor RB-005.17
The central methyl-substituted aromatic ring of 1 forms favorable
edge-on interactions with the side-chains of Phe259 and Phe389
while its methyl substituent packs against Leu385 and Leu286.
Unexpectedly, the side-chain of Thr282, one of the few non-
hydrophobic residues in the lipid binding site, does not form a
hydrogen bond to the ether oxygen of 1.
Compound 1 is reported to be a weak substrate for SPHK1.25
In order to be phosphorylated, its (R)-2-(hydroxymethyl)-
pyrrolidine head group would need to rotate ∼180° to bring the
primary hydroxyl into a position equivalent to that of the lipid
primary hydroxyl in PDB ID 3VZB26 (Figure 3). The need for
this rotation, which would break the two hydrogen bonds to
Asp264, provides a reasonable explanation for the weak substrate
activity of 1.
The loop containing residues 197−200 is in a diﬀerent
conformation in each of the two molecules in the asymmetric
unit. In chain A 197−200 are diﬀerent compared to previous
structures (Figure 3), being further away from the lipid binding
site, while in chain B 197−200 are partially disordered. This loop
is expected to be ﬂexible depending on the presence or absence
of bound ATP or ADP and may represent an opportunity for
inhibitor expansion. Use of the considerable space adjacent to
the head group of 1 could allow removal of the substrate activity,
as well as optimization of selectivity over all other enzymes in the
ceramide/sphingosine biosynthesis pathway.
Currently, research into the biological eﬀects and target
potential of the S1P biosynthetic pathway is hampered by the
lack of highly potent and selective inhibitors for either SPHK1
or SPHK2. This new structure of SPHK1 in complex with the
highest potency SPHK1 inhibitor published to date should aid
in the development of inhibitors with improved selectivity and
potency. Modeling of the binding of 1 to SPHK2 should aid the
development of highly potent and selective SPHK2 inhibitors,
of which none currently exist. SPHK2 has three residue dif-
ferences in the lipid binding site compared to SPHK1. Phe374
is Cys in SPHK2 (Figure 2A), while Ile260 is Val in SPHK2
and Met358 is Leu. All three of these diﬀerences make the
binding site larger in SPHK2 compared to SPHK1 suggesting
both that inhibitor expansion could create an SPHK2-speciﬁc
molecule and that it may be diﬃcult to create an SPHK1
inhibitor with no activity at all against SPHK2. The temperature
factors of inhibitor 1 in the structure suggest that the terminal
phenyl ring that binds against Phe374 may be the tightest bound
part of the molecule. Therefore, the substitution of Phe374 for
Cys in SPHK2 may be a signiﬁcant cause of the previously
observed ∼132-fold selectivity of 1 for SPHK1 over SPHK2.
Optimization of the interactions with Phe374 may aid further
improvement in SPHK1 selectivity, while enlargement of the
inhibitor to pack against Cys could promote SPHK2 selectivity.
There is potential for introduction of three-dimensional
inhibitor functionality to ﬁt the large central part of the lipid-
binding pocket, where the methyl-substituted aromatic ring of 1
binds. This is the where the adamantane ring of the SPHK2-
selective inhibitor ABC29464022 would be expected to bind. Given
the nonlinear binding shown by 1, a macrocyclic inhibitor might
also be possible. Introduction of suitable three-dimensionality
might be a way to gain selectivity over other enzymes in the
ceramide/sphingosine biosynthetic pathway where such enzymes
have linear lipid binding sites.
■ MATERIALS AND METHODS
Cloning. DNA for residues 81−449 of SPHK1 isoform 2
(NM_182965.2) was PCR ampliﬁed and subcloned into an in-house
pFastBac-based vector pFB-LIC-Bse29 using ligation-independent
cloning. The DNA template for SPHK1 isoform 2 was obtained from
the Mammalian Gene Collection (IMAGE Consortium Clone ID
4871343). The resulting construct expressed the desired protein with an
N-terminal hexahistidine tag and TEV (tobacco etch virus) protease tag
cleavage site (extension MGHHHHHHSSGVDLGTENLYFQ*SM-).
Protein Expression and Puriﬁcation. The construct DNA was
used to prepare recombinant baculovirus, which was used to infect
Sf 9 cells at a density of 2 million cells/mL in glass conical ﬂasks. The
ﬂasks were shaken at 27 °C for 48 h before cells were harvested by
centrifugation. The cells were resuspended in Binding Buﬀer (50 mM
Tris·HCl pH 7.8, 200 mM NaCl, 20 mM imidazole, 0.5 mM tris-
(2-carboxyethyl)phosphine (TCEP), and protease inhibitor cocktail
(Sigma-Aldrich)). The resuspended cells were frozen until further use.
For puriﬁcation the cells were thawed and lysed by sonication on ice.
PEI (polyethylenimine) was added to a ﬁnal concentration of 0.15%,
and the cell debris and precipitated DNA were spun down. The
supernatant was passed through a gravity column of 5 mL of Ni-
Sepharose resin (GE Healthcare). After washing the resin, the protein
was eluted with Binding Buﬀer containing 250 mM imidazole. The N-
terminal His tag was removed by addition of TEV (tobacco etch virus)
protease overnight at 4 °C, while the protein was dialyzed into GF
Buﬀer (20 mM Tris·HCl pH 7.8, 200 mM NaCl, and 0.5 mM TCEP).
The protein was passed through a column of Ni-Sepharose and then
concentrated to 5 mL volume and injected onto a S200 16/60 gel ﬁltration
column (GE Healthcare) pre-equilibrated into GF Buﬀer. Fractions
containing SPHK1 were pooled and concentrated to 10 mg/mL. Expected
molecular weight: 41120.1 Da. Measured molecular weight by electrospray
ionization: 41120.2 and 41201.8 Da (1× phosphorylation).
Structure Determination. Crystals were obtained using the
sitting drop vapor diﬀusion method at 4 °C. Crystals grew from a
mixture of 100 nL of SPHK1 protein (10 mg/mL with 1 mM PF-543
and 1 mM ADP) and 50 nL of a well solution containing 37.5% MPD,
0. One molar BisTris pH 5.5 and 0.1 M ammonium acetate. Crystals
were mounted in nylon loops before freezing in liquid nitrogen. Data
was collected at 100 K at the Diamond Synchrotron beamline I02.
Figure 3. Overlay of the binding PF-543 (1) (in green) and the lipid
seen in PDB ID 3VZB (in cyan) to SPHK1 (with N-terminal ATP-
binding domain in green and C-terminal lipid-binding domain in
blue). The alternative conformation of residues 197−200 in the lipid-
bound structure is shown in yellow.
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The diﬀraction data was indexed and integrated using XDS30 and
scaled using AIMLESS.31 The structure was solved by molecular
replacement using PHASER32 and the structure of SPHK1 (PDB ID
3VZB26) as the search model. There were two molecules of SPHK1
in the asymmetric unit. The model was built using Coot,33 reﬁned with
REFMAC5,34 and validated using MOLPROBITY.35 All structure
ﬁgures were created using PyMOL (Schrödinger LLC). Data collection
statistics can be seen in Table 1.
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